MRI image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands
US5236695A · kind A · utility
18Cited by
7References
48Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 11, 1991 |
| Grant date | Aug 17, 1993 |
| Priority date | — |
| Expiry date | Sep 11, 2011 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10T436/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Polyphosphonate ligands containing three or more phosphonate groups, combined with paramagnetic metal cations and administered in the form of pharmacologically acceptable salts, are useful as MRI contrast enhancement agents, which tend to localize in bone tissue without being conjugated to bone-specific biomolecules. Triazacyclononanes and tetraazacyclododecanes, with dihydroxyphosphorylmethyl or dihydroxyphosphorylethyl groups, optionally substituted at the methyl or ethyl bridges with alkyl, aryl, hydroxyl or amino groups, are particularly preferred.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.